Top Story

W&M GOP Working On Home Health Appeals Settlement As Providers Seek Relief

Home health providers and the American Medical Association are pushing for Medicare appeals settlements along the lines of the settlement CMS reached last year with hospitals, coming as Reps. Tom Price (R-GA) and Greg Walden (R-OR) get ready to unveil a home health bill that could pave the way for a settlement for that industry.

Latest News

As presidential nominees Hillary Clinton and Donald Trump were set to take the stage for their first debate, Sen. Amy Klobuchar (D-MN) told stakeholders at a Center for American Progress Action Fund briefing Monday (Sept. 26) she hoped drug pricing would be raised because it is the “number one thing” she has heard from a number of constituents.

Sen. Amy Klobuchar (D-MN) reminded stakeholders Monday (Sept. 26) that the administration could allow drug imports without new legislation from Congress.

Usage of hepatitis C drugs dropped 40 percent among Medicaid patients in 2015, according to pharmacy benefit manager Express Scripts, and most of that drop occurred in states that cover the drugs in fee-for-service Medicaid instead of letting private plans manage the drugs.

A bipartisan group of lawmakers led by Rep. Mike Fitzpatrick (R-PA) is pressing the Energy and Commerce Committee to hold hearings on ways to improve FDA’s ability to monitor and act on potentially deadly medical devices.

FDA approved Amgen’s first biosimilar product, a version of AbbVie’s Humira, Friday (Sept. 23), bringing the agency's total number of biosimilar approvals to four.

Rachel Sherman's appointment as FDA deputy commissioner for medical products and tobacco, coming nearly a year after rumors surfaced she would get the job, puts her in a formal position to shepherd high-profile agency policies.

The HHS Inspector General reports that the reimbursement scheme for home infusion inappropriately drives up the use of drugs by paying suppliers too much, but the National Home Infusion Association says the pay scheme doesn't drive overuse because physicians, not suppliers, prescribe drugs.

Utilizing big data and real-world evidence to assist in regulatory decision-making is a top priority of FDA's medical device center, according to a report published Tuesday (Sept. 20).